Division of Pulmonary and Critical Care Medicine, Philadelphia, PA; Department of Medicine, Temple University School of Medicine, Philadelphia, PA.
Division of Pulmonary and Critical Care Medicine, Philadelphia, PA; Department of Medicine, Temple University School of Medicine, Philadelphia, PA.
Chest. 2013 May;143(5):1444-1454. doi: 10.1378/chest.12-1801.
COPD is a leading cause of morbidity and mortality worldwide and is now the third leading cause of death in the United States. Acute exacerbations of COPD (AECOPDs) are common events that often lead to hospitalization, and their frequency worsens with disease progression. AECOPDs are associated with worsened quality of life, increased health-care costs, and increased mortality. Accordingly, there is great interest in preventing AECOPDs to improve outcomes. Both pharmacologic and nonpharmacologic interventions alter the frequency of AECOPDs and COPD-related hospitalizations. To examine the best available evidence, we restricted this review to include studies that used randomized controlled designs lasting at least 6 months. Pharmacologic interventions discussed include inhaled corticosteroids, long-acting β-agonists, long-acting antimuscarinic agents, macrolide antibiotics, and phosphodiesterase-4 inhibitors. The nonpharmacologic interventions discussed include lung volume reduction surgery, pulmonary rehabilitation, and disease management programs.
COPD 是全球范围内发病率和死亡率的主要原因,现已成为美国的第三大死因。COPD 的急性加重(AECOPD)是常见事件,常导致住院,且随着疾病进展,其频率会恶化。AECOPD 与生活质量下降、医疗费用增加和死亡率增加有关。因此,预防 AECOPD 以改善预后的兴趣很大。药物和非药物干预均可改变 AECOPD 和 COPD 相关住院的频率。为了检查最佳可用证据,我们将本综述限制在使用至少持续 6 个月的随机对照设计的研究。讨论的药物干预包括吸入皮质类固醇、长效β-激动剂、长效抗胆碱能药物、大环内酯类抗生素和磷酸二酯酶-4 抑制剂。讨论的非药物干预包括肺减容手术、肺康复和疾病管理计划。